NEW YORK (GenomeWeb) – Biocept said today that it has partnered with the University of California, San Diego on a clinical validation study of the company's Target Selector PD-L1 assay in patients diagnosed with non-small cell lung cancer (NSCLC).

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.